Literature DB >> 6266432

Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence.

J Palmblad, C L Malmsten, A M Udén, O Rådmark, L Engstedt, B Samuelsson.   

Abstract

We studied the effects of leukotrienes on in vitro functions of neutrophil polymorphonuclear (PMN) granulocytes. Leukotriene B4 (LTB4) evoked a stimulated and directed migration of neutrophils under agarose with an optimum concentration of 10(-6)M, whereas two nonenzymatically formed isomers (compounds I and II) induced this response at 10(-5)M. Leukotriene C4 (LTC4) and 5-hydroxyeicosate-traenoic acid (5-HETE) did not affect this PMN migration. At the same optimum concentrations, LTB4 and compounds I and II augmented PMN adherence to nylon fibers. The chemotactic and adherence responses were of the same magnitude as with formal-Met-Leu-Phe (fMLP) at 10(-7)M. None of the leukotrienes influenced the spontaneous or phagocytosis-associated chemiluminescence or the ability to kill Staphylococcus aures. The cyclooxygenase inhibitor, indomethacin, inhibited only partly the fMLP-induced migration at high concentrations and stimulated migration at 2.5 x 10(-7)M, suggesting that arachidonic acid was then mainly metabolized by the lipoxygenase pathways. The lipoxygenase and cyclooxygenase inhibitor, eicosatetraynoic acid, inhibited both spontaneous and stimulated migration at greater or equal to 2.5 x 10(-5)M, but not at lower concentrations. Thus, since LTB4, and to a lesser degree compounds I and II, stimulated migration and adhesion, it is suggested that these mediators could be of importance for the emigration of neutrophils from blood vessels to areas of inflammation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6266432

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  88 in total

Review 1.  Leukotriene activity modulation in asthma.

Authors:  S L Spector
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Chronic inflammation upregulates chemokine receptors and induces neutrophil migration to monocyte chemoattractant protein-1.

Authors:  B Johnston; A R Burns; M Suematsu; T B Issekutz; R C Woodman; P Kubes
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 3.  Big roles for small GTPases in the control of directed cell movement.

Authors:  Pascale G Charest; Richard A Firtel
Journal:  Biochem J       Date:  2007-01-15       Impact factor: 3.857

4.  Prostaglandin E2 Inhibits the Ability of Neutrophils to Kill Listeria monocytogenes.

Authors:  Michelle G Pitts; Sarah E F D'Orazio
Journal:  J Immunol       Date:  2019-05-06       Impact factor: 5.422

5.  Leukotrienes as mediators in ischemia-reperfusion injury in a microcirculation model in the hamster.

Authors:  H A Lehr; A Guhlmann; D Nolte; D Keppler; K Messmer
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

6.  Development and application of a membrane receptor assay for leukotriene B4.

Authors:  D M Patelunas; A P Agins; R E Zipkin; J B Smith
Journal:  Agents Actions       Date:  1989-06

7.  Effect of a leukotriene B4 receptor antagonist on leukotriene B4-induced neutrophil chemotaxis in cavine dermis.

Authors:  D J Fretland; D L Widomski; J M Zemaitis; S W Djurić; R L Shone
Journal:  Inflammation       Date:  1989-10       Impact factor: 4.092

8.  In vitro effects of leukotriene B4 (LTB4) on canine PMN effector function(s).

Authors:  D F Gruber; M M D'Alesandro; T L Walden
Journal:  Agents Actions       Date:  1989-11

9.  Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability.

Authors:  T R Martin; B P Pistorese; E Y Chi; R B Goodman; M A Matthay
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

10.  Granulocyte chemotaxis and disease expression are differentially regulated by GRK subtype in an acute inflammatory arthritis model (K/BxN).

Authors:  Teresa K Tarrant; Rishi R Rampersad; Denise Esserman; Lisa R Rothlein; Peng Liu; Richard T Premont; Robert J Lefkowitz; David M Lee; Dhavalkumar D Patel
Journal:  Clin Immunol       Date:  2008-07-26       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.